Medicure Inc. (MPH.V)
CAD 0.89
(14.1%)
CAD 0.89
(14.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -922 Thousand CAD | -167.55% |
| 2022 | 1.36 Million CAD | 287.76% |
| 2021 | -727 Thousand CAD | 89.38% |
| 2020 | -6.84 Million CAD | 65.4% |
| 2019 | -19.78 Million CAD | -604.02% |
| 2018 | 3.92 Million CAD | -90.96% |
| 2017 | 43.42 Million CAD | 57.0% |
| 2016 | 27.65 Million CAD | 1557.7% |
| 2015 | 1.66 Million CAD | -18.6% |
| 2014 | 2.04 Million CAD | 225.06% |
| 2013 | -1.63 Million CAD | 36.33% |
| 2012 | -2.57 Million CAD | -111.01% |
| 2011 | 23.38 Million CAD | 1261.1% |
| 2010 | -2.01 Million CAD | 63.59% |
| 2009 | -5.53 Million CAD | 58.45% |
| 2008 | -13.31 Million CAD | 76.8% |
| 2007 | -57.4 Million CAD | -81.06% |
| 2006 | -31.7 Million CAD | -151.47% |
| 2005 | -12.6 Million CAD | 15.19% |
| 2004 | -14.86 Million CAD | -148.22% |
| 2003 | -5.98 Million CAD | -42.81% |
| 2002 | -4.19 Million CAD | -8.22% |
| 2001 | -3.87 Million CAD | -19.9% |
| 2000 | -3.23 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 51 Thousand CAD | 103.29% |
| 2024 Q2 | -1.21 Million CAD | -2486.27% |
| 2023 Q2 | 253 Thousand CAD | -12.76% |
| 2023 FY | -922 Thousand CAD | -167.55% |
| 2023 Q1 | 290 Thousand CAD | -36.12% |
| 2023 Q3 | 84 Thousand CAD | -66.8% |
| 2023 Q4 | -1.54 Million CAD | -1942.86% |
| 2022 Q4 | 454 Thousand CAD | -59.21% |
| 2022 Q3 | 1.11 Million CAD | 262.96% |
| 2022 Q2 | -683 Thousand CAD | -241.7% |
| 2022 Q1 | 482 Thousand CAD | -74.72% |
| 2022 FY | 1.36 Million CAD | 287.76% |
| 2021 Q2 | -639 Thousand CAD | 39.03% |
| 2021 Q4 | 1.9 Million CAD | 301.59% |
| 2021 Q1 | -1.04 Million CAD | 75.92% |
| 2021 FY | -727 Thousand CAD | 89.38% |
| 2021 Q3 | -946 Thousand CAD | -48.04% |
| 2020 Q3 | -1.04 Million CAD | -5610.53% |
| 2020 FY | -6.84 Million CAD | 65.4% |
| 2020 Q1 | -1.46 Million CAD | 90.54% |
| 2020 Q2 | 19 Thousand CAD | 101.3% |
| 2020 Q4 | -4.35 Million CAD | -315.76% |
| 2019 Q1 | -2.75 Million CAD | -281.78% |
| 2019 FY | -19.78 Million CAD | -604.02% |
| 2019 Q2 | -957 Thousand CAD | 65.28% |
| 2019 Q3 | -599 Thousand CAD | 37.41% |
| 2019 Q4 | -15.47 Million CAD | -2483.31% |
| 2018 Q3 | -545.02 Thousand CAD | -134.17% |
| 2018 FY | 3.92 Million CAD | -90.96% |
| 2018 Q1 | 1.35 Million CAD | -97.36% |
| 2018 Q4 | 1.51 Million CAD | 378.17% |
| 2018 Q2 | 1.59 Million CAD | 17.34% |
| 2017 Q3 | -4.3 Million CAD | -417.91% |
| 2017 FY | 43.42 Million CAD | 57.0% |
| 2017 Q1 | -5.07 Million CAD | -120.78% |
| 2017 Q4 | 51.44 Million CAD | 1294.34% |
| 2017 Q2 | 1.35 Million CAD | 126.7% |
| 2016 Q3 | 2 Million CAD | 362.98% |
| 2016 Q2 | 432.7 Thousand CAD | -45.34% |
| 2016 FY | 27.65 Million CAD | 1557.7% |
| 2016 Q1 | 791.65 Thousand CAD | -46.31% |
| 2016 Q4 | 24.42 Million CAD | 1119.45% |
| 2015 Q2 | 441.33 Thousand CAD | 340.67% |
| 2015 Q4 | 1.47 Million CAD | 524.16% |
| 2015 Q1 | 100.15 Thousand CAD | 0.0% |
| 2015 FY | 1.66 Million CAD | -18.6% |
| 2015 Q3 | -347.64 Thousand CAD | -178.77% |
| 2014 Q3 | 1.34 Million CAD | 282.94% |
| 2014 Q2 | -736.54 Thousand CAD | -952.29% |
| 2014 Q1 | 86.42 Thousand CAD | 117.77% |
| 2014 FY | 2.04 Million CAD | 225.06% |
| 2013 Q2 | -706.53 Thousand CAD | 34.44% |
| 2013 FY | -1.63 Million CAD | 36.33% |
| 2013 Q4 | -486.42 Thousand CAD | 3.18% |
| 2013 Q3 | -502.4 Thousand CAD | 28.89% |
| 2013 Q1 | -1.07 Million CAD | -118.41% |
| 2012 Q1 | -352.95 Thousand CAD | -133.34% |
| 2012 Q2 | -861.62 Thousand CAD | -144.12% |
| 2012 Q3 | -296.74 Thousand CAD | 65.56% |
| 2012 Q4 | -493.39 Thousand CAD | -66.27% |
| 2012 FY | -2.57 Million CAD | -111.01% |
| 2011 Q2 | -1.88 Million CAD | -323.64% |
| 2011 Q3 | 23.54 Million CAD | 1351.64% |
| 2011 Q4 | 1.05 Million CAD | -95.5% |
| 2011 Q1 | 841.01 Thousand CAD | 15.38% |
| 2011 FY | 23.38 Million CAD | 1261.1% |
| 2010 Q3 | -1.7 Million CAD | -28.56% |
| 2010 Q4 | 728.89 Thousand CAD | 142.8% |
| 2010 FY | -2.01 Million CAD | 63.59% |
| 2010 Q1 | -2.12 Million CAD | -1104.12% |
| 2010 Q2 | -1.32 Million CAD | 37.56% |
| 2009 Q2 | 312.04 Thousand CAD | 108.56% |
| 2009 Q3 | -1.9 Million CAD | -711.95% |
| 2009 Q4 | -176.21 Thousand CAD | 90.77% |
| 2009 FY | -5.53 Million CAD | 58.45% |
| 2009 Q1 | -3.64 Million CAD | 47.76% |
| 2008 Q4 | -6.97 Million CAD | -131.85% |
| 2008 Q3 | -3 Million CAD | -11.22% |
| 2008 FY | -13.31 Million CAD | 76.8% |
| 2008 Q1 | -22.67 Million CAD | -33.85% |
| 2008 Q2 | -2.7 Million CAD | 88.07% |
| 2007 Q4 | -16.94 Million CAD | -12.32% |
| 2007 Q2 | -13.99 Million CAD | -67.35% |
| 2007 Q1 | -8.36 Million CAD | -37.3% |
| 2007 FY | -57.4 Million CAD | -81.06% |
| 2007 Q3 | -15.08 Million CAD | -7.74% |
| 2006 Q1 | -2.71 Million CAD | 23.18% |
| 2006 Q4 | -6.09 Million CAD | -87.72% |
| 2006 Q2 | -2.47 Million CAD | 8.81% |
| 2006 Q3 | -3.24 Million CAD | -30.93% |
| 2006 FY | -31.7 Million CAD | -151.47% |
| 2005 Q3 | -3.87 Million CAD | 19.41% |
| 2005 Q4 | -3.53 Million CAD | 8.61% |
| 2005 FY | -12.6 Million CAD | 15.19% |
| 2005 Q1 | -3.82 Million CAD | -5.33% |
| 2005 Q2 | -4.8 Million CAD | -25.76% |
| 2004 Q4 | -3.62 Million CAD | -38.67% |
| 2004 FY | -14.86 Million CAD | -148.22% |
| 2004 Q2 | -2.17 Million CAD | -48.2% |
| 2004 Q3 | -2.61 Million CAD | -20.23% |
| 2004 Q1 | -1.46 Million CAD | -17.72% |
| 2003 FY | -5.98 Million CAD | -42.81% |
| 2003 Q1 | -917.33 Thousand CAD | 21.77% |
| 2003 Q2 | -897.46 Thousand CAD | 2.17% |
| 2003 Q4 | -1.24 Million CAD | -13.39% |
| 2003 Q3 | -1.09 Million CAD | -22.51% |
| 2002 Q3 | -1.2 Million CAD | 0.0% |
| 2002 FY | -4.19 Million CAD | -8.22% |
| 2002 Q4 | -1.17 Million CAD | 2.79% |
| 2001 FY | -3.87 Million CAD | -19.9% |
| 2000 FY | -3.23 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.96 Million CAD | 68.901% |
| CanadaBis Capital Inc. | 4.44 Million CAD | 120.745% |
| Decibel Cannabis Company Inc. | -1.77 Million CAD | 47.91% |
| Delivra Health Brands Inc. | 876 Thousand CAD | 205.251% |
| Entourage Health Corp. | -46.16 Million CAD | 98.003% |
| Lifeist Wellness Inc. | -14.12 Million CAD | 93.473% |
| Cannara Biotech Inc. | 6.94 Million CAD | 113.275% |
| PharmaCielo Ltd. | -16.29 Million CAD | 94.343% |
| Rubicon Organics Inc. | -1.82 Million CAD | 49.439% |
| BioSyent Inc. | 6.46 Million CAD | 114.272% |
| Voyageur Pharmaceuticals Ltd. | -1.39 Million CAD | 34.118% |